Changes of bone metabolism in seven patients with gaucher disease treated consecutively with imiglucerase and miglustat

Calcified Tissue International

Volumn 83, Issue 1, 2008, Pages 43-54

  Mikosch, P ^a   Reed, M ^b   Baker, R ^b   Holloway, B ^b   Berger, L ^b   Mehta, A B ^b   Hughes, D A ^b  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bone metabolism; Gaucher disease; Imiglucerase; Miglustat

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLONY STIMULATING FACTOR 1; IMIGLUCERASE; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MIGLUSTAT; OSTEOCALCIN;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METABOLISM; BONE PAIN; CLINICAL ARTICLE; CLINICAL FEATURE; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG INFUSION REACTION; DRUG SUBSTITUTION; ENZYME REPLACEMENT; FEMALE; FLATULENCE; GAUCHER DISEASE; HEMATOLOGIC DISEASE; HEPATOMEGALY; HUMAN; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SPLENOMEGALY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREMOR;

1-DEOXYNOJIRIMYCIN; ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE DENSITY; BONE REMODELING; ENZYME INHIBITORS; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED;

EID: 50949128892     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-008-9143-4     Document Type: Article

References (38)

1. A Mehta 2006 Epidemiology and natural history of Gaucher's disease Eur J Intern Med 17 S2 S5
2. Hollak CE, Pastores GM (2004) Type I Gaucher disease. In: Zimran A (ed) Glycolipid storage disorders. Adis Communications, Abington, pp 17-26
3. RJ Wentrup M Roca-Espiau NJ Weinreb B Bembi 2002 Skeletal aspects of Gaucher disease: a review Br J Radiol 75 Suppl 1 A2 A12
4. DP Germain 2004 Gaucher's disease: a paradigm for interventional genetics Clin Genet 65 77 86
5. GA Grabowski NW Barton G Pastores JM Dambrosia TK Banerjee MA McKee C Parker R Schiffmann SC Hill RO Brady 1995 Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant resources Ann Intern Med 122 33 39
6. D Elstein A Abrahamov I Hadas-Halpern A Meyer A Zimran 1998 Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease QJM 91 483 488
7. CE Hollak JM Aerts R Goudsmit SS Phoa M Ek S van Weely AE von dem Borne MH van Oers 1995 Individualised low-dose alglucerase therapy for type 1 Gaucher disease Lancet 345 1474 1478
8. GM Pastores AR Sibille GA Grabowski 1993 Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months Blood 82 408 416
9. B Bembi G Ciana E Mengel MR Terk C Martini RJ Wentrup 2002 Bone complications in children with Gaucher disease Br J Radiol 75 Suppl 1 A37 A44
10. B Bembi M Zanatta M Carrozzi F Baralle R Gornati B Berra E Agosti 1994 Enzyme replacement treatment in type 1 and type 3 Gaucheŕs disease Lancet 344 1679 1682
11. P Giraldo P Latre P Alfonso A Acedo D Alonso A Barez A Corrales R Franco V Roldan S Serrano M Pocovi 2006 Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucheŕs disease Hematologica 91 703 706
12. D Elstein C Hollak JM Aerts S van Weely M Maas TM Cox RH Lachmann M Hrebicek FM Platt TD Butters RA Dwek A Zimran 2004 Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease J Inherit Metab Dis 27 757 766
13. GM Pastores NL Barnett EH Kolodny 2005 An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment Clin Ther 27 1215 1227
14. J Charrow B Dulisse GA Grabowski NJ Weinreb 2007 The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease Clin Genet 71 205 211
15. LW Poll JA Koch S vom Dahl R Willers A Scherer D Boerner C Niederau D Haussinger U Modder 2001 Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results Skeletal Radiol 30 496 503
16. LW Poll M Maas MR Terk M Roca-Espiau B Bembi G Ciana NJ Weinreb 2002 Response of Gaucher bone disease to enzyme replacement therapy Br J Radiol 75 Suppl 1 A25 A36
17. M de Fost CE Hollak JE Groener JM Aerts M Maas LW Poll MG Wiersma D Haussinger S Brett N Brill S vom Dahl 2006 Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood 108 850 855
18. RJ Wenstrup KA Kacena P Kaplan GM Pastores A Prakash-Cheng A Zimran T Hangartner 2007 Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease J Bone Miner Res 21 119 126
19. N Weinreb J Barranger S Packman A Prakash-Cheng B Rosenbloom K Sims J Angell A Skrinar GM Pastores 2007 Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease Clin Genet 71 576 588
20. G Pastores D Elstein M Hrebicek A Zimran 2007 Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational open-label studies Clin Ther 29 1645 1654
21. Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyiel M, Ronfani L, Vidoni L, Pittis MG, Bembi B (2005) Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28:723-732
22. G Ciana C Martini A Leopaldi G Tamoro F Katouzian L Ronfani B Bembi 2003 Bone marker alterations in patients with type 1 Gaucher disease Calcif Tissue Int 72 185 189
23. C Drugan G Jebeleanu P Grigorescu-Sido C Caillaud AM Craciun 2002 Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease Blood Cells Mol Dis 28 13 20
24. CE Fiore R Barone P Pennisi V Pavone S Riccobene 2002 Bone ultrasonometry, bone density, and bone turnover markers in type 1 Gaucher disease J Bone Miner Metab 20 24 38
25. A Mehta 2006 Clinical experience with substrate reduction therapy Eur J Intern Med 17 S13 S15
26. A Milligan D Hughes S Goodwin L Richfield A Mehta 2006 Intraveneous enzyme replacement therapy: better in home or hospital? Br J Nurs 15 330 333
27. M Maas C van Kuijk J Stoker CE Hollak EM Akkerman JF Aerts GJ den Heeten 2003 Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience Radiology 229 554 561
28. MJ Allen BJ Myer AM Khokher N Rushton TM Cox 1997 Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10 QJM 90 19 25
29. V Barak M Acker B Nisman I Kalickman A Abrahamov A Zimran S Yatziv 1999 Cytokines in Gaucher's disease Eur Cytokine Netw 10 205 210
30. MJ Breemen M de Fost JS Voerman JD Laman RG Boot M Maas CE Hollak JM Aerts F Rezaee 2007 Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease Biochim Biophys Acta 1772 788 796
31. N Udagawa N Takahashi T Akatsu H Tanaka T Sasaki T Nishihara T Koga TJ Martin T Suda 1990 Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells Proc Natl Acad Sci USA 87 7260 7264
32. GM Pastores NJ Weinreb H Aerts G Andria TM Cox M Giralt 2004 Therapeutic goals in the treatment of Gaucher disease Semin Hematol 41 4 14
33. MF Holick 2007 Vitamin D deficiency N Engl J Med 357 266 281
34. BW Hollis 2005 Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D J Nutr 135 317 322
35. A Zittermann 2003 Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89 552 572
36. CE Hollak L Evers JM Aerts MH van Oers 1997 Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease Blood Cells Mol Dis 23 201 212
37. S vom Dahl L Poll M Di Rocco G Ciana C Denes G Mariani M Maas 2006 Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients Curr Med Res Opin 22 1045 1064
38. B Czartoryska A Tylki-Szymańska A Lugowska 2000 Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease Clin Biochem 33 147 149